Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc. (Nasdaq: DYN) is a clinical-stage biopharmaceutical company focused on developing functional improvement therapies for people living with genetically driven neuromuscular diseases. The company's proprietary FORCE platform leverages the transferrin receptor 1 to deliver targeted therapeutics to… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Dyne Therapeutics, Inc. does
In the company’s own words
Dyne Therapeutics, Inc. (Nasdaq: DYN) is a clinical-stage biopharmaceutical company focused on developing functional improvement therapies for people living with genetically driven neuromuscular diseases. The company's proprietary FORCE platform leverages the transferrin receptor 1 to deliver targeted therapeutics to muscle tissue and the central nervous system. The platform utilizes an antigen-binding fragment antibody targeting TfR1 conjugated to rationally designed payloads, including oligonucleotides and enzymes, that address the genetic basis of disease.
Dyne's pipeline includes multiple product candidates in varying stages of preclinical and clinical development. The company's lead program, zeleciment rostudirsen, is being evaluated in the DELIVER Phase 1/2 trial for Duchenne muscular dystrophy amenable to exon 51 skipping, with plans for a U.S. Accelerated Approval submission in the second quarter of 2026. Zeleciment basivarsen is in the ACHIEVE Phase 1/2 trial for myotonic dystrophy type 1, with anticipated U.S. Accelerated Approval submission planned for early third quarter of 2027. Additional development candidates target facioscapulohumeral dystrophy and Pompe disease, with plans to expand into additional neuromuscular indications.
The company employs over 250 individuals with expertise spanning discovery, preclinical research, manufacturing, clinical development, and commercial operations. Dyne maintains global commercial rights to all its programs and has established scientific and clinical advisory boards comprising leading experts in muscle disease drug discovery and nucleic acid therapeutics.
The company's strategy centers on advancing its co-lead product candidates through development and commercialization, establishing a DMD franchise by expanding to additional patient populations, and building a sustainable leadership position in neuromuscular diseases. Dyne has received multiple regulatory designations including Breakthrough Therapy, Fast Track, Rare Pediatric Disease, and Orphan Drug designations for its lead programs from the FDA and EMA. The company operates with a patient-focused culture emphasizing commitment to delivering life-transforming therapeutics for serious neuromuscular diseases.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- WALTHAM, MA
- Fiscal year end
- December
- CIK
- 1818794
- SIC
- 2834
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Dyne Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Dyne Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Dyne Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Dyne Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Dyne Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”